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Background: The emergence of multidrug-resistant tuberculosis (MDR-TB) is a threat to 
successful TB treatment outcomes in developing nations like Nigeria. This study 
determined the predictors of intensive phase treatment outcomes in MDR-TB patients in 
Zaria, Nigeria.  
 
Methods:   This was a retrospective cross-sectional review of the records of 124 MDR-TB 
patients registered between September 2012 and August 2017 at the National 
Tuberculosis and Leprosy Training Centre, Saye, Zaria. Data were analyzed using IBM 
SPSS version 25.0 and the StataCorp STATA/SE 14. 
 
Results:  The median age (IQR) of the respondents was 32 (15) years. The gene Xpert test 
detected Mycobacterium Tuberculosis (MTB) and rifampicin resistance (RIF) in 119 
(96.0%) cases. The treatment success rate was 97 (78.2%). MDR-TB and HIV co-infection 
rate was 17 (13.7%) while the case fatality rate was 16.1%. Bivariate analysis showed 
that being male (p=0.001), not currently in marital union (p=0.01) and positive smear 
results at 1 month (p=0.027)) were significantly associated with treatment success. 
Multivariate logistic regression showed that the odds for successful treatment outcome 
was 4 times higher for the MDR-TB patients who were employed than the unemployed 
(AOR= 3.98, 95% CI= 1.15-13.74). No significant relationship between MDR-TB-HIV 
comorbidity (AOR=1.89, 95% CI=0.44-8.19), MDR-TB susceptible to Isoniazid (AOR= 
0.49, 95% CI =0.15-1.56) and successful treatment outcome. 
 
Conclusion: Unemployment was a predictor of poor treatment outcome in this study. 
Cause-specific mortality due to the MDR TB was high in this setting. We advocate for 
optimization of access to treatment and social support system, especially for the female 
patients. 
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The World Health Organization Global 
Tuberculosis report showed that an 
estimated 10 million people from different 
parts of the world developed Tuberculosis 
(TB) in 2017.  The cause-specific death 
rate from this chronic infection was 
estimated at 1.3 million globally. 1 Nigeria 
harbours 4% of the global TB burden and 
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the country is currently regarded as the 
6th most-affected TB nation in the world 
after India (27%), China (9%), Indonesia 
(8%), Philippines (6%) and Pakistan (5%).1 
This undesirable TB morbidity is 
worsened by the emergence of Multidrug 
Resistant-TB (MDR-TB) which occurs 
when there is the resistance of the 
mycobacterium tuberculosis to at least 
two of the most effective first-line anti-
tuberculous drugs, Rifampicin and 
Isoniazid.2, 3  
When MDR-TB is not properly treated due 
to various health system challenges in 
developing countries, there can be disease 
progression to extensively drug-resistant 
TB (XDR-TB); which is MDR-TB with 
additional resistance to any of the 
fluoroquinolone and the second-line 
injectable Anti-TB drugs; such as 
Amikacin, Kanamycin or Capreomycin.4,5 
Another variant of the MDR-TB which is 
the total resistance to all available anti-TB 
drugs (TDR-TB) has been reported in some  
TB endemic settings.6 The emergence and 
spread of MDR-TB is gradually becoming 
an epidemic in low-and-middle-income 
countries due to ignorance of the disease, 
treatment delays, client mismanagement 
and poor adherence to the treatment 
guidelines.7 
A previous report in 2013 in Nigeria 
estimated the prevalence of MDR-TB to be 
2.9% among newly detected cases and 
14.5% in previously treated cases, 8 while 
another study conducted in 2014 showed 
that about 3600 MDR-TB cases occur 
annually among the notified pulmonary 
TB patients in the country with poor 
treatment outcome.9 The increasing trend 
of this variant of TB implies that 
healthcare stakeholders in the MDR-TB 
endemic communities need to identify the 
specific drivers of this infection in their 
localities for effective prevention and 
control measures. The MDR-TB and its 
progressive variants (XDR-TB and TDR-
TB) are more costly to manage, 10 have the 
propensity for increased transmission to 
community and family members,11   
present with worse cure rates 12, 13 and 
usually affect mostly the productive 
workforce population.14-16   The prevention 
and management of these conditions, 
therefore are quintessential for the 
communities’ and states’ socioeconomic 
development.   
The bacteriological confirmation for the 
MDR-TB involves the use of the molecular 
test, Xpert MTB/RIF assay to detect the 
resistance pattern or through other rapid 
drug sensitivity testing (DST) to capture 
the sensitivity pattern of all the available 
anti-tuberculous drugs used for the 
treatment of the infection. 17, 18 
Following a confirmatory diagnosis, an 
MDR-TB patient in whom there is no 
resistance to fluoroquinolones or second-
line injectable drugs is commenced on the 
WHO recommended shorter regimen for 9-
12 months, which is different from the 
previously used longer regimen of 18 
months.19 This shorter regime has two 
treatment phases; the intensive phase and 
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the continuation phase. During the 
intensive phase, the patients are 
commenced on some second-line anti-
tuberculosis drugs including Kanamycin 
(KN), Moxifloxacin (MFX), Clofazimine 
(CFZ), Ethionamide (ETO), Pyrazinamide 
(Z), Ethambutol (E) and High dose 
Isoniazid (H) daily for four months. The 
change of the therapy to the continuation 
phase regimen at the fifth month is 
usually based on sputum smear 
conversion and clinical response. 
Treatment failure occurs when the patient 
remains sputum smear and/or culture-
positive at six months.  This will require a 
switch to an individualized regimen. 20 The 
continuation phase for the shorter 
regimen consists of high dose 
moxifloxacin (MFX), clofazimine (CFZ), 
Ethambutol (E) and pyrazinamide (Z)  for 
a fixed duration of five months.20 Patients 
diagnosed with HIV and co-morbid drug-
resistant TB are commenced on highly 
active antiretroviral therapy (HAART) after 
starting the directly observed treatment 
short-course (DOTs) as early as possible, 
within the first eight weeks, as 
recommended by the WHO and adopted in 
the Nigeria national guideline for drug-
resistant tuberculosis management.20-22 
The TB HIV co-infection has been shown 
to complicate TB treatment by prolonging 
the duration and severity of the TB 
infection; resulting in poor treatment 
outcomes 23  
Previously MDR-TB patients were 
managed exclusively at the TB referral 
hospitals but the new WHO Model for 
MDR-TB care currently includes a 
combination of ambulatory rather than 
only hospitalization.24,25 This management 
option allows for better drug adherence, 
adequate monitoring of adverse reactions, 
regular sputum smear and culture 
examination, and multi-disciplinary 
management of the patients.26 
Literature from developing countries have 
attributed specific mortality due to MDR 
TB to be very high during the intensive 
phase.27–29   Studies on the outcome of 
MDR TB drug treatment are very scarce in 
Nigeria despite being a high TB endemic 
nation. This study, therefore, examines 
the determinants of the outcome of the 
intensive phase management in MDR-TB 
patients at the National TB Reference 
Centre in Saye, Zaria, north-western 
Nigeria.  
METHODOLOGY  
This was a retrospective review of medical 
records of all the 124 MDR-TB patients 
who were registered between September 
2012 and August 2017 at the National 
Tuberculosis, Buruli Ulcers and Leprosy 
Training Centre (NTBLTC), Saye Zaria. 
The NTBLTC Nigeria was established in 
1991 as the Human Resource 
Development Unit of the National 
Tuberculosis, Buruli Ulcers and Leprosy 
Control Programme (NTBLCP) of the 
Federal Ministry of Health, Nigeria. It 
serves both as a training Centre and a 
referral hospital with an estimated 180 
bed capacity for drug-susceptible TB, 
TB/HIV, MDR-TB, Leprosy and other 
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common dermatological cases. Twenty of 
the bed spaces are isolated in a separately 
fenced building for the management of 
MDR-TB patients.  
The study population were all clients with 
the MDR-TB confirmed by Gene Xpert and 
Drug sensitivity testing (DST) whose 
record files could be retrieved from the 
medical record department of the facility. 
The plan to exclude those with incomplete 
records was not applicable as all the 
available records contained the relevant 
information for the study. The required 
data were extracted from the patients’ 
files, collated, cleaned and entered into 
the computer for both descriptive and 
inferential analysis using the IBM SPSS 
Statistics for Windows, Version 25.0. 
(Armonk, NY: IBM Corp) and StataCorp 
STATA/SE 12 (StataCorp.2011; Stata 
Statistical Software: Release 12, College 
Station, TX; StataCorp LP).  
The frequencies and the percentages of 
the socio-demographic and clinical 
profiles of the patients were computed, 
while bivariate analysis through chi-
square test statistic was used to test the 
associations between patients’ socio-
demographic variable and MDR-TB 
treatment outcome. 
The level of statistical significance was set 
at p <0.05. The primary outcome variable 
was the MDR-TB treatment outcome, 
which was categorized as: Completed 
intensive phase; Treatment discontinued; 
Referred; Left against medical advice or 
Died. 
The predictor variables identified from the 
patients’ records were age, sex, year of 
treatment, place of residence, occupation, 
marital status and HIV comorbidity. 
Bivariate and multivariate logistic 
regression analysis were carried out 
against these sets of independent 
variables to determine the predictors of a 
successful outcome of MDR-TB intensive 
phase management. 
Ethical approval (NTBLTC/ZA/HREC 
/001/86) for the study was obtained from 
the Research and Ethical Committee of 
the National Tuberculosis and Leprosy 
Training Centre, Saye, Zaria. Since this 
was a routinely collected programme data, 
informed consent from the patients was 
not obtained, but the safety of the clinical 
record and patient confidentiality was 
ensured.   
RESULTS 
A total of 124 records of MDR-TB patients 
were extracted from the registers. The 
median (IQR) age of the patients is 32 (15) 
years. Children less or equal to 14 years 
were 7 (6%).  Majority of the MDR TB 
patients were males 87 (70.2%), more 
than half (53.2%) were married and mostly 
unemployed 75 (60.5%). The clients were 
from Kaduna State 37 (29.8%), other 
states constituted 87 (70.2%) (Table 1) The 
clinical profile of the MDR-TB patients 
shows that treatment after failure was 64 
(51.6%), new patients were only 29 
(23.4%), relapsed MDR  19 (15.3%), return 
after follow-up 7 (5.6%) and other 
previously treated 5 (4.0%).  The 
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HIV/MDR comorbidity was 17 (13.7%).  
Most of the clients, 109 (87.9%) were 
treated with the longer regimen, only 15 
(12.1%) were managed on the shorter 
regimen.  About four-fifth, 97 (78.2%) 
completed the intensive phase and were 
cured, five (4.0%) discontinued treatment, 
two clients (1.6%) left against medical 
advice and 20 (16.1%) died. (Table 2) 
 
Table 1: Socio-demographics 
characteristics of MDR-TB patients at the 
NTBLTC, Saye Zaria 2012-2017 

































































































Table 3 shows that the Xpert MTB/RIF 
assay detected MTB and rifampicin 
resistance (RIF) in 119 (96%) cases.   
There were 68 (54.8%) of the clients 
susceptible to INH while 56 (45.2%) were 
resistant cases. The DST also isolated 
some resistant strains to Ethambutol 
13(10.5%) and streptomycin 15(12%). No 
resistance to fluoroquinolone was 
reported. 
Bivariate analysis as seen in Table 4 
showed that the male sex (χ2 10.9, 
p=0.001), not currently married (χ2 =6.03, 
p=0.01) and positive smear results at one 
month after initiation of treatment 
(χ2=4.91, p=0.027) were associated with 
successful treatment outcome. 
Multivariate logistic regression further 
showed that the odds for successful 
treatment outcome was about 4 times 
higher (AOR= 3.98, 95% CI=1.15-13.74) 
for the employed than for the unemployed. 
There was also increased odds (AOR=3.61, 
95%CI =0.9-14.53) for the successful 
treatment outcome among those not 
currently married than the currently 
married patients. The odds were however 
insignificantly lower for the MDR TB cases 
susceptible to Isoniazid (AOR=0.49, 
95%CI = 0.15-1.56) and negative smear 
result after 1 month on DoT (AOR=0.32. 
95%CI=0.07-1.29). The HIV positive 
patients had insignificantly increased 
odds (AOR=1.89, 95%CI=0.44-8.19) for 
successful treatment outcome (AOR, 0.44, 
95% CI= 0.09-2.15) than for the HIV 
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Table 2: Clinical profile of the MDR-TB patients at the NTBLTC, Saye, Zaria 2012-2017 
Clinical profile  Frequency (n=124) Percent 
Type of patient  
New 
Relapse  
Treatment after failure  
Returned after loss to follow 
up 





























Longer (18 months) 





































Intensive phase Rx outcome  
  
Completed intensive phase 97 78.2 
Treatment discontinued 5 4.0 
Left against medical advice 2 1.6 
Died  20 16.1 
 
*A patient who does not fit into other case definition, for example patient treated outside the NTBLTC 
network, but still smear positive for TB 
 
 
Table 3:   Result of laboratory gene Xpert and Drug Sensitivity Test for the MDR TB in Zaria  
  
Gene expert  Frequency (n=124) Percent 
Rifampicin  
MTB detected RIF detected 
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DISCUSSION  
The majority of the people affected in this 
study were the young, workforce age 
group of the Kaduna state population. 
This corroborates previous reports on 
tuberculosis, which showed that the age 
group usually affected by this infection 
were the young adults who constitute the 
productive workforce of the population. 28, 
29.    
 
Most of the women with the MDR-TB in 
this study were mother care-givers of 
estimated 6% children affected with the 
MDR-TB in this survey.  
This corroborates the earlier report that 
infected mother- caregivers were the 
major route of transmission and spread of 
the Childhood MDR TB. 30-32 
 
 
Table 4:  Bivariate analysis of clients’ socio-demographics, clinical profile and treatment outcome 
for MDR TB in Zaria  
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TABLE 5: Multivariate logistic regression of the determinants of successful treatment outcome for 
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p-value 
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This survey also showed that more males 
were infected and treated for the MDR-TB 
than the females, similar to studies from 
Malaysia and Morocco. 33, 34 The treatment 
outcome in this study was poorer among 
the female. This finding is different from 
most previous studies where poorer 
treatment outcomes were observed among 
the male folk 35, 36 Community surveys 
using a mixed-method approach and 
other exploratory studies need to be 
conducted on gender differentials and 
MDR-TB treatment outcome in this 
setting.  
Most of the MDR-TB in this survey were 
sequel to previous TB treatment failure.  
Previous studies had identified poor 
adherence to the first-line TB drugs as a 
major reason for the treatment failure and 
subsequent progression to the MDR TB.37, 
38 This emphasized the need for TB 
treatment centres to practice drug 
adherence policy including the strict 
demand for reliable treatment supporters 
as a prerequisite for the initiation of the 
MDR TB therapy at the Directly Observed 
Therapy (DOTs) clinics. Dallo et al had 
reported that the poor application of the 
DOTs which leads to the poor adherence 
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to the anti-TB drugs was a major risk 
factor for treatment failure and 
subsequent progression to MDR-TB in 
Burkina Faso.39   
 Our study also found that unemployment 
was a predictor of a poorer treatment 
outcome for the MDR-TB. This 
underscores the need for the adequate 
assessment of the patients’ socioeconomic 
status at the onset of treatment and 
provision of some form of financial 
incentives for the indigent patients to 
cater for their indirect treatment cost. 40 
We also noted the treatment outcome for 
the MDR-TB patients with resistance to 
both Rifampicin and Isoniazid did not 
significantly differ from Rifampicin 
Resistant Tuberculosis (RR-TB). Other 
previous studies had reported poorer 
treatment outcome for the MDR TB 
involving the two core Anti TB drugs. 41,42 
The Gene Xpert test conducted in this study 
detected mycobacterium tuberculosis and 
rifampicin resistance in almost all the 
patients similar to a Pakistan MDR TB 
survey43. Also, the relatively few DST 
isolated resistance to Isoniazid, 
Ethambutol and Streptomycin reported 
were comparable to a report from a 
Moroccan study. 44   We have no case of 
resistance to fluoroquinolone nor 
pyrazinamide in this study, which means 
that there was no indication for the 
individualized regimen .45 A study in China 
reported that MDR TB with resistance to a 
fluroquinolone was also a predictor of poor 
treatment outcomes.46 The cure rate of  
78.2%   during the intensive phase in this 
study was lower than the WHO 
recommended target cure rate of 85% but 
slightly higher than the successful 
treatment outcomes of most other studies 
in Nigeria, which ranged from 46-62%. 
47,48 
We could not establish any significant 
difference between HIV comorbidity and 
MDR TB treatment outcome in this study. 
This is different from a finding in a survey 
in South Africa where MDR-TB and HIV 
co-infection were less likely to have a 
successful treatment outcome compared 
to HIV negative patients.49 The high 
mortality rate in this study (16%) is a 
thing of concern.  This was higher than 
previous MDR-TB specific death rates in 
some previous studies 50, 51 though lower 
than the   MDR-TB mortality reported in a 
study from South Africa. 52 
The limitation of this study was that of 
utilizing a secondary data source which 
contained limited variable for data 
analysis to determine the treatment 
outcome.  There was also the possibility of 
information bias at the time of this facility-
based data collection.  
This study has shown that the 
socioeconomic status of the MDR TB 
patient is a major determinant of the 
treatment outcome. Unemployment was 
the risk factor which predicts poor 
treatment outcome. These group of 
patients need increased access to 
treatment which is essential to prevent 
adverse treatment outcomes such as the 
TB treatment failure, TB relapse, MDR-TB 
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and MDR-TB and HIV co-morbidity. 53 
There is also a need for adequate social 
support systems, and TB programme with 
a focus on women empowerment to 
enhance better treatment outcomes. 54 
The authors also recommend further 
studies to determine factors responsible 
for lost to follow-up or discontinuation of 
treatment by MDR TB patients in this 
setting 55 
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